Legal & General Group
KROS icon

Legal & General Group’s Keros Therapeutics KROS Stock Holding History

Legal & General Group’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$90K Buy
8,410
+5,789
+221% +$64.5K ﹤0.01% 2650
2026
Q1 		$28.9K Hold
2,621
– – ﹤0.01% 2841
2025
Q4 		$53.4K Sell
2,621
-496
-16% -$8.7K ﹤0.01% 2718
2025
Q3 		$49.3K Hold
3,117
– – ﹤0.01% 2733
2025
Q2 		$41.6K Sell
3,117
-2,837
-48% -$38.3K ﹤0.01% 2748
2025
Q1 		$60.7K Sell
5,954
-26,016
-81% -$302K ﹤0.01% 2713
2024
Q4 		$506K Buy
31,970
+2,855
+10% +$148K ﹤0.01% 2450
2024
Q3 		$1.69M Hold
29,115
– – ﹤0.01% 2045
2024
Q2 		$1.33M Buy
29,115
+3,660
+14% +$197K ﹤0.01% 2099
2024
Q1 		$1.69M Buy
25,455
+6,579
+35% +$390K ﹤0.01% 2003
2023
Q4 		$751K Sell
18,876
-50
-0.3% -$1.57K ﹤0.01% 2308
2023
Q3 		$603K Buy
18,926
+830
+5% +$31K ﹤0.01% 2363
2023
Q2 		$727K Buy
18,096
+8,549
+90% +$375K ﹤0.01% 2333
2023
Q1 		$408K Buy
9,547
+1,464
+18% +$73.9K ﹤0.01% 2376
2022
Q4 		$388K Buy
8,083
+442
+6% +$20.6K ﹤0.01% 2397
2022
Q3 		$287K Buy
7,641
+752
+11% +$26.1K ﹤0.01% 2491
2022
Q2 		$190K Buy
6,889
+35
+0.5% +$1.54K ﹤0.01% 2655
2022
Q1 		$373K Buy
6,854
+704
+11% +$36.1K ﹤0.01% 2475
2021
Q4 		$360K Buy
6,150
+6
+0.1% +$299 ﹤0.01% 2518
2021
Q3 		$243K Buy
6,144
+2,519
+69% +$89.6K ﹤0.01% 2624
2021
Q2 		$154K Buy
3,625
+209
+6% +$11.3K ﹤0.01% 2604
2021
Q1 		$211K Sell
3,416
-64
-2% -$4.05K ﹤0.01% 2447
2020
Q4 		$245K Buy
3,480
+2,642
+315% +$166K ﹤0.01% 2380
2020
Q3 		$32K Sell
838
-290
-26% -$11.5K ﹤0.01% 2827
2020
Q2 		$42K Buy
+1,128
New +$34.8K ﹤0.01% 2769

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Legal & General Group's KROS Position: Q2 2026 in Review

Legal & General Group increased its Keros Therapeutics (KROS) stake by 221% in Q2 2026, buying an estimated $64.5K and bringing the position to 8,410 shares worth $90K. The position accounts for ﹤0.01% of the portfolio, ranked #2650.

Legal & General Group first reported a position in KROS in Q2 2020 and has held it in 25 quarters since. The position peaked at $1.69M in Q3 2024. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Legal & General Group held 8,410 shares of Keros Therapeutics worth $90K as of Q2 2026.
  • Legal & General Group bought 5,789 Keros Therapeutics shares in Q2 2026, an estimated $64.5K.
  • Keros Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2650 holding.
  • Legal & General Group first reported a position in Keros Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • Legal & General Group's Keros Therapeutics position peaked at $1.69M in Q3 2024.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.